Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 378-384, 2009. First published December 23, 2008; 10.1373/clinchem.2008.115899
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2008.115899v1
55/2/378    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilson, P. W.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, P. W.F.
Related Collections
Right arrow Special Interest Papers for ACC Cardiologists
(Clinical Chemistry. 2009;55:378-384.)
© 2009 American Association for Clinical Chemistry, Inc.

Preamble

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease

NACB LMPG Committee Members, Gary L. Myers, (Chair)1,a, Robert H.M. Christenson, (Vice-Chair)2, Mary Cushman3, Christie M. Ballantyne4, Gerald R. Cooper1, Christine M. Pfeiffer1, Scott M. Grundy5, Darwin R. Labarthe1, Daniel Levy6, Nader Rifai7, Peter W.F. Wilson8

1 Centers for Disease Control and Prevention, Atlanta, GA; 2 University of Maryland School of Medicine, Baltimore, MD; 3 University of Vermont, Colchester, VT; 4 Baylor College of Medicine, Houston, TX;5 University of Texas Southwestern Medical Center, Dallas, TX; 6 Framingham Heart Study, Framingham, MA; 7 Children’s Hospital and Harvard Medical School, Boston, MA; 8 Emory University School of Medicine, Atlanta, GA.

aAddress correspondence to this author at: Centers for Disease Control and Prevention, 4770 Buford Hwy. NE (F25), Atlanta, GA 30341. Fax (770) 488-0333; e-mail gmyers{at}cdc.gov.


Abstract

Background: Heart disease and stroke continue to be the leading causes of death in the US. As a result, investigators continue to look for new and emerging biomarkers of disease risk. Because many of these emerging biomarkers are not as well documented as those of conventional lipid and lipoprotein risk factors, their value in clinical practice needs to be critically appraised and appropriate guidelines developed for their proposed use.

Content: The National Academy of Clinical Biochemistry (NACB) convened a multidisciplinary expert panel to develop laboratory medicine practice guidelines for a selected subset of these emerging risk factors as applied in a primary prevention setting of heart disease and stroke. The NACB expert panel selected lipoprotein subclasses and particle concentration, lipoprotein(a), apolipoproteins A-I and B, high sensitivity C-reactive protein (hsCRP), fibrinogen, white blood cell count, homocysteine, B-type natriuretic peptide (BNP), N-terminal proBNP (NT-proBNP), and markers of renal function as biomarkers that fell within the scope of these guidelines.

Conclusions: Based on a thorough review of the published literature, only hsCRP met all of the stated criteria required for acceptance as a biomarker for risk assessment in primary prevention.




The following articles in journals at HighWire Press have cited this article:


Home page
 Circ Cardiovasc Qual OutcomesHome page
P. M Ridker
The JUPITER Trial: Results, Controversies, and Implications for Prevention
Circ Cardiovasc Qual Outcomes, May 1, 2009; 2(3): 279 - 285.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.